(Press-News.org) April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults with chronic HCV GT1 infection and chronic kidney disease (CKD) classified as stage 4 or stage 5, received 12 weeks of treatment with ombitasvir / paritaprevir / ritonavir and dasabuvir (3D) either with or without ribavirin. There was a 24-week post-treatment follow-up period. As of February 18 2015, 17 of a planned 20 patients in Cohort 1 had received treatment and six had completed treatment. The combination has been well tolerated to date, with no treatment-related serious adverse events, one hemoglobin decline to END
Prelim. safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients
Safety findings from the ongoing RUBY-1 study evaluating ombitasvir / paritaprevir / ritonavir in combination with dasabuvir (3D) in chronic hepatitis C virus (HCV) genotype 1 (GT1) patients with severe renal impairment or end-stage renal disease
2015-04-25
ELSE PRESS RELEASES FROM THIS DATE:
Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing
2015-04-25
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
Use of pocket-sized ultrasound device reduces need for further testing in clinical settings
2015-04-25
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...
Hepatitis C screening essential to help catch patients with advanced liver fibrosis
2015-04-25
April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...
Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment
2015-04-25
Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards.
Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted ...
Mental disorders don't predict future violence
2015-04-25
Depression is not linked to violence among males
Some delinquent youth with current psychiatric illness may be violent
Providing treatment could reduce violence
CHICAGO --- Most psychiatric disorders - including depression -- do not predict future violent behavior, according to new Northwestern Medicine longitudinal study of delinquent youth. The only exception is substance abuse and dependence.
"Our findings are relevant to the recent tragic plane crash in the French Alps. Our findings show that no one could have predicted that the pilot - who apparently ...
Drug prices to treat multiple sclerosis soar, point to larger problem
2015-04-24
PORTLAND, Ore. - A new study released today found that drugs used to treat multiple sclerosis have soared in price in the past two decades, in some cases more than 700 percent, even though newer drugs have come to the market - a process that normally should have stabilized or reduced the cost of at least the older medications.
There are no multiple sclerosis drugs now available in the United States with a list price below $50,000 a year, which is two to three times more than the price in Canada, Australia or the United Kingdom. The group of drugs available to treat this ...
Team develops faster, higher quality 3-D camera
2015-04-24
When Microsoft released the Kinect for Xbox in November 2010, it transformed the video game industry. The most inexpensive 3-D camera to date, the Kinect bypassed the need for joysticks and controllers by sensing the user's gestures, leading to a feeling of total immersion into the game. Microsoft sold 8 million Kinect units within 60 days, making it the fastest-selling electronic device ever.
"But then something interesting happened," said Oliver Cossairt, assistant professor of electrical engineering and computer science at Northwestern University's McCormick School ...
Northwestern scientists develop first liquid nanolaser
2015-04-24
Northwestern University scientists have developed the first liquid nanoscale laser. And it's tunable in real time, meaning you can quickly and simply produce different colors, a unique and useful feature. The laser technology could lead to practical applications, such as a new form of a "lab on a chip" for medical diagnostics.
To understand the concept, imagine a laser pointer whose color can be changed simply by changing the liquid inside it, instead of needing a different laser pointer for every desired color.
In addition to changing color in real time, the liquid ...
FDG PET/CT not useful in staging newly diagnosed stage III invasive lobular breast cancer
2015-04-24
TORONTO, April 20, 2015-- Although National Comprehensive Cancer Network (NCCN) guidelines consider 18F-PET/CT (FDG PET/CT) appropriate for systemic staging of newly diagnosed stage III breast cancer, the technique may not be equally valuable for all breast cancer histologies. Researchers at the Memorial Sloan Kettering Cancer Center found that while FDG PET/CT is valuable for systemic staging of stage III ductal breast cancer, it adds little to the systemic staging of ILC.
"We are evaluating patient and disease factors that affect the value of FDG PET/CT for systemic ...
Text messaging useful for reaching 'at-risk' teens about sex
2015-04-24
PULLMAN, Wash. - Text messaging that connects teens with sexual health educators is effective for delivering sexual health information, according to a recent study in The Edward R. Murrow College of Communication at Washington State University.
The research abstract is online and the work will appear in an upcoming print issue of the journal Health Education and Behavior.
"What we found is that teens identified as 'at-risk' use this text messaging service at a higher rate that other teens," said Jessica Willoughby, lead investigator on the project and an assistant professor ...
LAST 30 PRESS RELEASES:
Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in treating a common form of irritable bowel syndrome, pilot study finds
Experts developing immune-enhancing therapies to target tuberculosis
Making transfusion-transmitted malaria in Europe a thing of the past
Experts developing way to harness Nobel Prize winning CRISPR technology to deal with antimicrobial resistance (AMR)
CRISPR is promising to tackle antimicrobial resistance, but remember bacteria can fight back
Ancient Maya blessed their ballcourts
Curran named Fellow of SAE, ASME
Computer scientists unveil novel attacks on cybersecurity
Florida International University graduate student selected for inaugural IDEA2 public policy fellowship
Gene linked to epilepsy, autism decoded in new study
OHSU study finds big jump in addiction treatment at community health clinics
Location, location, location
Getting dynamic information from static snapshots
Food insecurity is significant among inhabitants of the region affected by the Belo Monte dam in Brazil
The Society of Thoracic Surgeons launches new valve surgery risk calculators
Component of keto diet plus immunotherapy may reduce prostate cancer
New circuit boards can be repeatedly recycled
Blood test finds knee osteoarthritis up to eight years before it appears on x-rays
April research news from the Ecological Society of America
Antimicrobial resistance crisis: “Antibiotics are not magic bullets”
Florida dolphin found with highly pathogenic avian flu: Report
Barcodes expand range of high-resolution sensor
DOE Under Secretary for Science and Innovation visits Jefferson Lab
Research expo highlights student and faculty creativity
Imaging technique shows new details of peptide structures
MD Anderson and RUSH unveil RUSH MD Anderson Cancer Center
Tomography-based digital twins of Nd-Fe-b magnets
People with rare longevity mutation may also be protected from cardiovascular disease
Mobile device location data is already used by private companies, so why not for studying human-wildlife interactions, scientists ask
Test reveals mice think like babies
[Press-News.org] Prelim. safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patientsSafety findings from the ongoing RUBY-1 study evaluating ombitasvir / paritaprevir / ritonavir in combination with dasabuvir (3D) in chronic hepatitis C virus (HCV) genotype 1 (GT1) patients with severe renal impairment or end-stage renal disease